Literature DB >> 25708358

Low frequency of PAX8-PPARγ rearrangement in follicular thyroid carcinomas in Japanese patients.

Kunio Mochizuki1, Tetsuo Kondo, Naoki Oishi, Ippei Tahara, Tomohiro Inoue, Kazunari Kasai, Tadao Nakazawa, Takahiro Okamoto, Noriyuki Shibata, Ryohei Katoh.   

Abstract

Paired-box gene 8 (PAX8)-peroxisome proliferator-activated receptor-γ (PPARγ) gene fusion has been identified at significant frequency in follicular thyroid carcinomas (FTCs) with cytogenetically detectable translocation t(2;3)(q13;p25). This represents a possible specific molecular marker for follicular carcinoma. In this study, we examined PAX8-PPARγ rearrangement in 24 FTC samples from Japanese patients by reverse transcribed-polymerase chain reaction (RT-PCR) using two upstream PAX8 primers located in exons 7 and 8 and a downstream primer in exon 1 of PPARγ. The fusion gene was detected in only one of 24 FTCs (4%). The FTC with PAX8-PPARγ rearrangement from a 56-year-old man showed a product consistent with fusion between exon 8 of PAX8 and exon 1 of PPARγ. It was confirmed by direct sequencing. This FTC was histologically encapsulated, composed of trabeculae and small follicles and had complete penetration of the capsule by tumor tissues (minimally invasive type). The frequency of the fusion gene in this study was much lower than the 29-63% noted in reports from other countries suggesting that FTCs in Japanese patients may have a special genetic background, and that the high iodine intake from a typical Japanese diet might influence the frequency of the fusion gene in FTCs.
© 2015 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  Japanese; PAX8; PPARγ; follicular thyroid carcinoma; rearrangement

Mesh:

Substances:

Year:  2015        PMID: 25708358     DOI: 10.1111/pin.12270

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  3 in total

1.  Mutation profiles of follicular thyroid tumors by targeted sequencing.

Authors:  Huanli Duan; Xiaoding Liu; Xinyu Ren; Hui Zhang; Huanwen Wu; Zhiyong Liang
Journal:  Diagn Pathol       Date:  2019-05-10       Impact factor: 2.644

Review 2.  Refractory thyroid carcinoma: which systemic treatment to use?

Authors:  Laurence Faugeras; Anne-Sophie Pirson; Julian Donckier; Luc Michel; Julien Lemaire; Sebastien Vandervorst; Lionel D'Hondt
Journal:  Ther Adv Med Oncol       Date:  2018-01-23       Impact factor: 8.168

3.  Mutational burdens and evolutionary ages of thyroid follicular adenoma are comparable to those of follicular carcinoma.

Authors:  Seung-Hyun Jung; Min Sung Kim; Chan Kwon Jung; Hyun-Chun Park; So Youn Kim; Jieying Liu; Ja-Seong Bae; Sung Hak Lee; Tae-Min Kim; Sug Hyung Lee; Yeun-Jun Chung
Journal:  Oncotarget       Date:  2016-10-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.